{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=37",
    "query": {
      "intervention": "Formulation #1",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 1758,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T01:14:48.656Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04876807",
      "title": "A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ACP-196",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acerta Pharma BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2016-01-28",
      "completion_date": "2016-03-15",
      "has_results": false,
      "last_update_posted_date": "2021-05-07",
      "last_synced_at": "2026-11-04T01:14:48.656Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04876807"
    },
    {
      "nct_id": "NCT05176626",
      "title": "Long-term Effectiveness of the Antiobesity Medication Phentermine",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity",
        "Obesity; Drug",
        "Lifestyle, Healthy"
      ],
      "interventions": [
        {
          "name": "Online Lifestyle Behavioral Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Phentermine Hydrochloride 8 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 870,
      "start_date": "2022-06-30",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-11-04T01:14:48.656Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Saint Louis Park, Minnesota • Winston-Salem, North Carolina + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05176626"
    },
    {
      "nct_id": "NCT03839693",
      "title": "ET-01 in Subjects With Lateral Canthal Lines, LCL-208",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lateral Canthal Lines",
        "Crow's Feet"
      ],
      "interventions": [
        {
          "name": "botulinum toxin, Type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vehicle",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eirion Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 65 Years · Female only"
      },
      "enrollment_count": 75,
      "start_date": "2018-10-16",
      "completion_date": "2019-09-19",
      "has_results": true,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-11-04T01:14:48.656Z",
      "location_count": 5,
      "location_summary": "Miami, Florida • Pinellas Park, Florida • Louisville, Kentucky + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pinellas Park",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03839693"
    },
    {
      "nct_id": "NCT00347360",
      "title": "The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "lisinopril",
          "type": "DRUG"
        },
        {
          "name": "carvedilol controlled release formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 654,
      "start_date": "2006-07",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2016-12-26",
      "last_synced_at": "2026-11-04T01:14:48.656Z",
      "location_count": 151,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Haleyville, Alabama + 131 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00347360"
    },
    {
      "nct_id": "NCT03736720",
      "title": "Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Digestive System Neuroendocrine Carcinoma",
        "Locally Advanced Pancreatic Neuroendocrine Carcinoma",
        "Metastatic Digestive System Neuroendocrine Carcinoma",
        "Metastatic Pancreatic Neuroendocrine Carcinoma",
        "Refractory Digestive System Neuroendocrine Carcinoma",
        "Refractory Pancreatic Neuroendocrine Carcinoma",
        "Unresectable Digestive System Neuroendocrine Carcinoma",
        "Unresectable Pancreatic Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-06-17",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2025-01-30",
      "last_synced_at": "2026-11-04T01:14:48.656Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Stony Brook, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03736720"
    },
    {
      "nct_id": "NCT06099782",
      "title": "A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab (+) Berahyaluronidase alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2023-12-26",
      "completion_date": "2027-02-15",
      "has_results": true,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-11-04T01:14:48.656Z",
      "location_count": 8,
      "location_summary": "Alexander City, Alabama • Anchorage, Alaska • Springdale, Arkansas + 5 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06099782"
    },
    {
      "nct_id": "NCT00397735",
      "title": "N-acetylcysteine in Intra-amniotic Infection/Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Labor, Premature",
        "Preterm Premature Rupture of the Membranes",
        "Infection",
        "Inflammation",
        "Chorioamnionitis"
      ],
      "interventions": [
        {
          "name": "amniocentesis",
          "type": "PROCEDURE"
        },
        {
          "name": "N-acetylcysteine or placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 68,
      "start_date": "2006-10-01",
      "completion_date": "2018-08-01",
      "has_results": false,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-11-04T01:14:48.656Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Columbus, Ohio",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00397735"
    },
    {
      "nct_id": "NCT00996268",
      "title": "An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "GSK2212836",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 46,
      "start_date": "2009-10-15",
      "completion_date": "2010-01-04",
      "has_results": false,
      "last_update_posted_date": "2017-06-22",
      "last_synced_at": "2026-11-04T01:14:48.656Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00996268"
    },
    {
      "nct_id": "NCT04311710",
      "title": "A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumor"
      ],
      "interventions": [
        {
          "name": "ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        },
        {
          "name": "ENHANZE (rHuPH20)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2020-06-25",
      "completion_date": "2023-01-18",
      "has_results": false,
      "last_update_posted_date": "2023-02-24",
      "last_synced_at": "2026-11-04T01:14:48.656Z",
      "location_count": 2,
      "location_summary": "Hartford, Connecticut • Fort Wayne, Indiana",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04311710"
    },
    {
      "nct_id": "NCT01944423",
      "title": "Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Nicotine Addiction",
        "Panic Attack"
      ],
      "interventions": [
        {
          "name": "d-cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Pill Placebo",
          "type": "DRUG"
        },
        {
          "name": "Nicotine replacement therapy",
          "type": "DRUG"
        },
        {
          "name": "Panic and Smoking Reduction Treatment",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Texas at Austin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 53,
      "start_date": "2013-10",
      "completion_date": "2018-10",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-11-04T01:14:48.656Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01944423"
    }
  ]
}